Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
different degrees of adjustment of the injection interval
The First People's Hospital of Lianyungang
Exudative Age-Related Macular Degeneration
1 trial -
diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis
Ultragenyx UK Limited
Pertussis
1 trial -
donor lymphocyte infusion
The First People's Hospital of Lianyungang
Minimal Residual Disease
1 trial -
doxorubicin hydrochloride
United Therapeutics Europe Ltd
Stage III Bladder Cancer
1 trial -
doxorubicin in combination with palifosfamide-tris
Alaunos Therapeutics
Soft Tissue Sarcoma
1 trial -
ecallantide
Takeda
Hereditary Angioedema (HAE)
4 trials -
educational internet site on prostate cancer screening
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
eltrombopag
GlaxoSmithKline
Hepatitis C, Chronic
1 trial -
enfortumab vedotin, VINFLUNINE , DOCETAXEL , PACLITAXEL
Astellas Pharma GmbH
Locally advanced or metastatic urothelial cancer
1 trial -
erlotinib
Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
esophagectomy
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
eteplirsen
Sarepta Therapeutics
Duchenne Muscular Dystrophy (DMD)
2 trials -
evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)
Wuhan Createrna Science and Technology Co., Ltd
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
1 trial -
exemestane
Partner Therapeutics Limited
Breast Cancer
1 trial -
extended-release naltrexone (XR-NTX)
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine-dependence
1 trial -
eythrocytapheresis
Atrium Therapeutics
Pre Operative Autologous Donation
1 trial -
fitusiran
Sanofi Pasteur
Hemophilia A
1 trial -
fixed dose combination of telmisartan+amlodipine
Boehringer Ingelheim
Hypertension
1 trial -
gemcitabine
NORTHWEST BIOTHERAPEUTICS INC
Non-Small Cell Lung Cancer
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
gene expression analysis
United Therapeutics Europe Ltd
Kidney Cancer
1 trial -
giroctocogene fitelparvovec
Pfizer Australia Pty Ltd
hemophilia A
1 trial -
giroctocogene fitelparvovec, fidanacogene elaparvovec
Pfizer Australia Pty Ltd
hemophilia A, severe to moderately severe hemophilia B (FIX:C β€ 2%)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources